Skip Navigation

European Heart Journal 1982 3(6):542-545;
Copyright © 1982 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by SIMOONS, M. L.
Right arrow Articles by VAN DOMBURG, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SIMOONS, M. L.
Right arrow Articles by VAN DOMBURG, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1982 by The European Society of Cardiology

Alinidine, a new agent which lowers heart rate in patients with angina pectoris

M. L. SIMOONS, J. TUMMERS, H. VAN MEURS-VAN WOEZIK and R. VAN DOMBURG

The Thoraxcenter, Erasmus University The Netherlands

Received 26 June 1981; revised 16 December 1981; .

Requests for reprints to: Maarten L. Simoons, MD, The Thorax-center, Erasmus University, P.O.B. 1738, 3000 DR Rotterdam, The Netherlands.

Abstract

Alinidine has been shown to reduce heart rate in experimental animals and in humans. However, in contrast with the beta blockers, this effect is not mediated through adrenergic receptors.

The potential value of this drug was tested in eight patients with coronary artery disease and stable angina pectoris. During a one-week period of hospitalisation, exercise tests were done on four successive days after administration of placebo, 20, 40 and 60 mg alinidine, in a randomized double-blind sequence. On each day, exercise tests were performed on a bicycle ergometer with workload increments of 20 W/min until angina or fatigue. A dose-dependent reduction of heart rate and of the rate-pressure product was observed after alinidine. Rate-pressure products at peak exercise were 242 ± 42, 218 ± 29, 206 ± 33 and 197 ± 33 after placebo and ascending doses of alinidine, respectively. Exercise tolerance improved by a mean of 16 W, while the highest load which was achieved without symptoms improved by 26 W with 60 mg of alinidine. It is concluded that alinidine reduces myocardial oxygen consumption and improves exercise tolerance in patients with angina. Its ultimate clinical value should be further evaluated in larger groups of patients.

Key Words: Alinidine • exercise test • heart rate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
S. Yusuf and A. J. Camm
Sinus Tachyarrhythmias and the Specific Bradycardic Agents: A Marriage Made in Heaven?
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 89 - 105.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.